Biomedicines and Bacterial Translocation in Spondyloarthritis

• Status: Not yet recruiting
• Trial end date: 2025-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this project is to evaluate the effect of anti-TNF and anti-IL17 biotherapies on bacterial translocation in patients with NSAID-resistant axial spondyloarthritis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Besancon
• Treatments: Antibodies; Immunoglobulins

Criteria

Inclusion Criteria:

• Axial spondyloarthritis (2009 ASAS criteria)

• NSAID arm: Responding to any class of NSAID and not likely to initiate biotherapy

• anti-TNF/anti-IL-17 arms: Need to introduce a biomedical drug according to current recommendations (objective signs of inflammation, i.e. MRI sacroiliitis or increased CRP, and failure of two NSAIDs of different classes)

Exclusion Criteria:

• IBD already diagnosed by a gastroenterologist or suspicion of IBD (bloody diarrhea)

• Previous exposure to a biomedical drug (anti TNF or anti IL 17).

• Antibiotic use in the 3 months prior to inclusion

• Contraindications for treatment with anti-TNF or anti-IL17 (for all patients)